Trisomy of chromosome 11 (+11) is the second most common isolated trisomy in acute myeloid leukemia (AML) patients.
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The presence of +11 is associated with intermediate 2, 3 or poor patient outcomes. [4] [5] [6] Whereas the clinical characteristics of solitary +11 have been well established, [4] [5] [6] relatively little is known about the mutational landscape of sole +11 AML in the age of nextgeneration sequencing techniques that allow examination of multiple genes relevant to AML pathogenesis. 6 So far, the most common molecular feature in AML with isolated +11 is the presence of a partial tandem duplication of the MLL (KMT2A) gene (MLL-PTD), which is detectable in up to 90% of patients. 7 Furthermore, a frequent co-occurrence of the FLT3 internal tandem duplication (FLT3-ITD) with MLL-PTD has been reported. 8 The aim of our study was to better characterize the mutational landscape of adult AML patients with sole +11.
Bone marrow (BM) or blood samples containing ⩾ 20% leukemic blasts were obtained from 23 AML patients with isolated +11 identified from among 1625 adult AML patients with diagnostic material available for molecular studies. Thus, the frequency of sole +11 in our AML patient cohort was 1.4%. Pretreatment cytogenetic analyses of BM and/or blood samples were performed by Cancer and Leukemia Group B (CALGB)/ Alliance for Clinical Trials in Oncology (Alliance)-approved institutional laboratories and the results centrally reviewed. Trisomy 11 (found in ⩾ 2 metaphase cells; Supplementary Table S1) was the only clonal chromosome abnormality detected in each patient in pretreatment specimens subjected to unstimulated 24-and/or 48-h culture. The patients were treated on CALGB/ Alliance trials (for details, see Supplementary Information). Study protocols were in accordance with the Declaration of Helsinki and approved by the institutional review boards at each center, and all patients provided written informed consent.
Definitions of the clinical end points (complete remission (CR), disease-free (DFS) and overall (OS) survival) and statistical methods are provided in the Supplementary Information. Data collection and statistical analyses were performed by the Alliance for Clinical Trials in Oncology Statistics and Data Center. The study database was locked on 8 December 2015.
The mutational status of 80 protein coding genes (see Supplementary Information for experimental procedures, analyses algorithm and achieved sequencing depth) was determined by targeted amplicon sequencing using the MiSeq platform (Illumina, San Diego, CA, USA). Testing for the presence or absence of FLT3-ITD, MLL-PTD and mutations in CEBPA was performed as previously described (see Supplementary Information). Thus, since FLT3 and MLL were also part of the 80-gene-targeted amplicon panel, our approach allowed the assessment of the mutational status of 81 genes.
Additionally, RNA from all patients with available material (n = 18) was used for RNA sequencing studies (RNAseq; Supplementary Information). Mutations detected in the targeted sequencing approach at the DNA level were also analyzed at the RNA level by visual inspection of the BAM files.
The clinical characteristics and outcomes of 23 patients with sole +11 are summarized in Table 1 . The patients were Only those genes that have been found mutated in at least one patient are listed in the Table in alphabetical order. No mutations were detected in the following genes: AKT1, ARAF, ATM, BCL2, BRAF, BRD4, BRINP3, BTK, CCND1, CCND2, CEBPA (biallelic), CTNNB1, EZH2, FBXW7, GATA1, GATA2, GSK3B, HIST1H1E, HNRNPK, IKZF1, IKZF3, IL7R, JAK2, JAK3, KIT, KLHL6, KMT2A (other than PTD), MAPK1, MAPK3, MYD88, NOTCH1, NPM1, PHF6, PIK3CD, PIK3CG, PLCG2, PLEKHG5, PRKD3, PTEN, RAD21, RAF1, SAMHD1, SETBP1, SF1, SF3A1, SF3B1, SMARCA2, SMC3, SYK, TGM7, TP53, TYK2, U2AF2, XPO1 and ZMYM3. Patients who received an allogeneic hematopoietic stem cell transplantation in first CR (n = 4) were excluded from the disease-free survival analysis.
Letters to the Editor predominantly older, with 18 patients (78%) over the age of 60 years. They were older than the remaining patients in the total patient cohort who did not have sole +11 (median, 71 vs 52 years; Po 0.001). Only 13% of the isolated +11 patients had signs of extramedullary involvement of their leukemia. The outcomes of sole +11 AML patients were very poor. Only 11 (48%) patients achieved a CR, and 54% of those who did eventually relapsed. Both DFS and OS were short, with medians of 12.5 and 11.7 months and 36-month rates of 14% and 11%, respectively (Table 1) . However, three of four patients who received allogeneic stem cell transplantation in first CR were alive and disease-free for more than 3 years.
Results of mutational analyses performed using the targeted sequencing panel are shown in Table 1 and Figure 1a . Ninety-two mutations were found in 28 of the 81 tested genes, with a median of four mutations per patient (range, 1-6 mutations). All mutations detected at the DNA level were also validated at the RNA level if the gene was adequately covered in the RNAseq (Supplementary  Table S1 ). Strikingly, mutations in only five genes accounted for 62% of the mutational load (57/92 mutations) of the patients: MLL-PTD (detected in 70% of patients), U2AF1 (48%) and DNMT3A (48%; R882, n = 7 and non-R882, n = 4) mutations, FLT3-ITD (43%) and IDH2 (39%) mutations. All sole +11 patients harbored at least one of these five gene mutations. Other gene mutations were found in only a few patients. FLT3-TKD, SRSF2 and ZRSR2 mutations were each detected in three patients, and IDH1, MED12, PTPN11, RUNX1, STAG2 and TET2 mutations each in two patients in our cohort. Fourteen genes were mutated in single cases only (Table 1) . With the exception of IDH2 and U2AF1, which were mutually exclusive, the five dominating gene mutations (MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2) frequently co-occurred. Most patients harbored more than one of these five mutations, with a median of three (range: 1-4).
Whereas DNMT3A and IDH2 are among the most frequently mutated genes in AML patients, 9 U2AF1 mutations are rare in AML. 10, 11 Initially discovered in~10% of patients with myelodysplastic syndrome, 10 they occur in roughly 20% of chronic Figure 1 . Distribution of recurrent mutations, and prognostic impact of mutations in the DNMT3A gene in patients with AML and sole +11.
(a) Oncoprint of recurrent mutations found in 23 sole +11 patients analyzed. Red indicates the presence of a gene mutation, grey, wild-type status, and white, mutation status not determined. Depicted separately at the top of the figure are the five genes, which we found commonly mutated in sole +11 patients. Only genes mutated in two or more patients are included in the oncoprint. s-AML denotes secondary AML; t-AML, therapy-related AML. (b) Overall survival of older (aged ⩾ 60 years) AML patients with sole +11 according to the presence or absence of mutations in the DNMT3A gene. The presence of a DNMT3A mutation was the only factor significantly associated with reduced overall survival in our analysis. myelomonocytic leukemia patients, 11 but have not been hitherto associated with any specific AML subset. U2AF1 mutations are considered as early (possibly disease-initiating) leukemogenic events since they were detected at the earliest presentation of chronic myelomonocytic leukemia. 11 The effects of mutant U2AF1 on hematopoiesis and myeloid neoplasms are profound; they include significantly altering hematopoiesis and pre-mRNA splicing in vitro and in vivo. 10 Notably, while U2AF1 mutations can usually be found in two hotspot positions of the gene (S34 and Q84), 10 all sole +11 patients were mutated only at the S34 hotspot. Interestingly, sole +11 is now the second isolated trisomy associated with a specific spliceosome gene mutation. Previously, Herold et al.
12 found~80% of AML patients with isolated trisomy 13 to harbor mutations in SRSF2.
Our data confirm MLL-PTD and, to a lesser extent, FLT3-ITD as common events in +11 AML. [6] [7] [8] However, the high mutation frequencies of U2AF1 and genes involved in methylation (DNMT3A, IDH2) have hitherto not been reported in +11 AML. It has been shown that in cases with +11 and MLL-PTD only one chromosome contains the MLL-PTD and the remaining two chromosomes harbor wild-type MLL alleles. 13 Yet, despite having two wild-type alleles, the MLL wild-type transcript is not expressed in primary blasts harboring MLL-PTD. 13 This phenomenon can be reversed with DNA methyltransferase and histone deacetylase inhibitor treatment, suggesting epigenetic modifications to be responsible for the allele-specific expression.
14 It is tempting to speculate that mutations in DNMT3A and/or IDH2 may contribute to the epigenetic changes in +11 AML, including differential activation of the wild-type MLL transcript.
Notably, DNMT3A, U2AF1 and IDH2 mutations (which were determined by the targeted sequencing panel) were always present at high VAFs (430%), suggesting that they represent early mutational events. The percentages of cells with +11 in pretreatment samples (based on cytogenetic analysis in all cases and fluorescence in situ hybridization in two) were also high in most cases (Supplementary Table 1 ). The vast majority of patients (19 of 23, 83%) had ⩾ 60% of cells with sole +11 (including 11 patients with 100% of +11-positive cells), whereas in only 4 patients (17%) cells with sole +11 constituted a minority, 10 − 30%, of the analyzed cells. Thus, it seems that in most instances gain of chromosome 11 represents an important, early alteration, whereas in a smaller subset of patients +11 might represent a cooperating rather than an initiating event.
We tested whether any of the clinical or molecular pretreatment parameters influenced the probability of achieving CR, DFS or OS of sole +11 patients. Since patients younger than 60 years and those aged 60 years or more were treated differently, and there were only five younger patients, the outcome analyses were performed in patients aged ⩾ 60 years. We found that the presence of DNMT3A mutations (R882 and non-R882 combined) was associated with a lower probability to achieve a CR (P = 0.02, Supplementary Table S2), with only 1 of 8 (13%) patients with a DNMT3A mutation achieving a CR compared with 7 of 10 (70%) patients with wild-type DNMT3A. Moreover, the presence of DNMT3A mutations was also associated with shorter OS (P = 0.004; median, 6.8 vs 22.5 months; Figure 1b and Supplementary Table S2) . No other gene mutation was associated with any outcome end point in our analyses. Our findings are consistent with the recent report by Kao et al., 15 who identified co-occurring DNMT3A mutations as an unfavorable prognostic factor in AML patients harboring MLL-PTD, most of whom had a normal karyotype. However, because of the relatively small number of patients analyzed, our results concerning the prognostic impact of DNMT3A mutations in sole +11 AML are preliminary and warrant further studies.
Taken together, although our analyses are limited by a relatively small sample size, our study sheds new light on the mutational background of this prognostically adverse subset of AML patients with sole +11. Residual disease in chronic myeloid leukemia (CML) patients undergoing therapy with tyrosine kinase inhibitors (TKIs) is measured by assessing the quantity of transcripts of the BCR-ABL1 fusion gene in peripheral white blood cells. 1 This analysis is based on reverse-transcription quantitative PCR (RT-qPCR) technology; however, the wide array of methods used worldwide has led to large variation in quantitative BCR-ABL1 measurements, which hamper inter-laboratory comparative studies. 2, 3 It is now recognized that monitoring BCR-ABL1/control gene ratios on the International Scale (IS) is vital for the management of patients with CML. 4 Efforts to harmonize procedures to measure BCR-ABL1 fusion transcripts have included important investments in sample exchange programs to derive laboratory-specific conversion factors (CF); these efforts showed improvements in interlaboratory concordance rates, but the process is laborious and limited due to the lack of a common set of reference samples that can be shared on a global scale. This requirement was recently addressed in part by the formulation and validation of the first World Health Organization (WHO) International Genetic Reference Panel for quantitation of BCR-ABL1 by RT-qPCR. 5 The WHO primary standards consist of a four-level panel of e14a2-positive lyophilized cell line dilutions. Each level has an assigned IS value, which was obtained by repeated testing of each sample level in expert IS-standardized laboratories. Unfortunately, the stock of WHO primary standards is limited, and their accessibility has been restricted to manufacturers of testing kits or secondary reference standards. In this study, we aimed to develop and validate secondary reference materials calibrated to the IS through the WHO primary standards in order to facilitate standardization of molecular monitoring in Latin America.
The study design comprised five principal steps as illustrated in Supplementary Figure 1 . The study was conducted by a single reference laboratory (rLAB, Buenos Aires, Argentina), which initially obtained a CF to the IS by sample exchange with the reference laboratory in Adelaide in 2010. To ensure consistent performance of the rLAB analytical system (MolecularMD, Portland, OR, USA), we included two quality control RNA samples with a high and low BCR-ABL1 level in each run (Supplementary Table 1 and Supplementary Material and Method, Section 1). To further validate our method prior to calibration of secondary reference materials (see below), we derived a CF by using WHO primary standards (NIBSC code 09/138) from the United Kingdom National Institute for Biological Standards and Control (Potters Bar, Hertfordshire, UK). The antilog of the estimated mean bias (−0.152) was designated as the conversion factor (CF = 0.7) for the rLAB method (Supplementary Table 2 ), which is very close (that is, well within twofold) to the value of 0.45 obtained by sample exchange 3 years previously.
Previous local exploratory investigation indicated that RT-qPCR methodology harmonization was necessary since the tests were inadequately comparable, considering that the three acceptance criteria proposed by Muller et al. 6 were not satisfied (Supplementary Tables 3 and 4) . To this aim, we established and validated five batches of cellular calibrators produced by serial dilution of the Ph-positive cell line K562 in the Ph-negative cell line HL-60. Formulations were planned to target IS% ratios close to each of the established TKI clinical response criteria, [7] [8] [9] that is, between 10%, 1%, 0.1% (MR 3.0 ) and 0.01% (MR 4.0 ). An additional dilution (0.001%, MR 5.0 ) was included in order to assess the limit of detection of the methods and was not considered for the estimation of the CF (Figure 1 ). Cell mixes were stabilized by lyophilization (Supplementary Figure S2A) ; assignment of IS% values to each batch and level of these secondary standards was achieved by repeated testing of randomly picked ampoules on 4 non-consecutive days (Figure 1 and Supplementary Material and Method, Section 2). Stability studies of the freeze-dried cells showed no significant changes in the BCR-ABL1/ABL1 ratio over time at different temperatures up to 6 months (Supplementary Figure 2B) . The calibrated secondary reference standards were Accepted article preview online 25 July 2016; advance online publication, 19 August 2016
